Text size Moderna is developing two vaccines for the fall, one for the U.S. and the other for international markets. Sean Gallup/Getty Images As the U.S. prepares for a broad Covid-19 booster campaign...
Tag: MRNA
U.S. Secures 3.2 Million Novavax Covid Vaccines — Offering Alternative To MRNA Shots As New Variant Spreads
Topline The Biden administration announced Monday it has secured 3.2 million doses of the two-dose Novavax Covid-19 vaccine, which it plans to release for free pending emergency authorization from the...
Pfizer Raises Covid-19 Vaccine Price 27%. What It Means for the Stock.
Text size Pfizer said it has signed a deal to supply the U.S. with vaccines in the fall, while Moderna has yet to announce a sale. Jacob King – WPA Pool / Getty Images Pfizer has raised the U.S....
U.S. Stocks Poised to Open Lower on Monday Ahead of Fed Week
Stocks are poised to open lower on Monday. (Photo by Spencer Platt/Getty Images) Getty Images Text size U.S. stocks were poised for a lower opening on Monday ahead of the Federal Reserve’s decision on...
Federal Reserve Meeting, Oracle and Adobe Earnings, May Inflation Data, and More for Investors to Watch This Week
It will be a quiet week on the earnings calendar between earnings seasons. The most important event of the week for investors will be the conclusion of the Federal Reserve’s interest rate-setting comm...
Cruise line stocks suffer sharp losses, again
Shares of cruise operators suffered sharp declines for a second-straight session, amid signs of declining pricing and what that might mean for demand. Carnival Corp.’s CCL, -9.28% CCL, -2.65% st...
Novavax’s New Covid-19 Vaccine Might Be Late to the Party
It’s one thing to arrive fashionably late to a party, it’s another thing to waltz in when the last guests are stumbling out the door. For Novavax , which on Tuesday cleared a key step toward U.S. Food...
Moderna Sees X3 Covid Vaccine Sales in Q1 2022, MRNA Stock Jumps 7%
Except for its recent jump, Moderna stock has been at the lows. The remarkable Q1 2022 performance may give Moderna a boost and help its stock to rebound. Moderna Inc (NASDAQ: MRNA) gained about 8% in...
Moderna Stock Falls Despite Vaccine Sales More Than Tripling From Last Year
Topline Shares of Moderna dropped on Wednesday even after the biotech company reported higher-than-expected revenue and profits in the first quarter, with results boosted by soaring coronavirus vaccin...
Covid Moderna (MRNA) Q1 earnings 2022
The Moderna Covid-19 vaccine awaits administration at a vaccination clinic in Los Angeles, California on December 15, 2021. Frederic J. Brown | AFP | Getty Images Moderna sold $5.9 billion of its Covi...
What to Look For From MRNA
Key Takeaways Analysts estimate EPS of $5.83 vs. $2.84 in Q1 FY 2021. Revenue is expected to rise at a rapid pace, but much slower than in recent quarters. Moderna recently applied for an EUA for use ...
James Anderson of Baillie Gifford on Illumina, Moderna, and Other Companies That Matter
James Anderson, a partner at Scottish money manager Baillie Gifford, has personified growth-stock investing during his 39 years with the firm. He was an early backer of Amazon.com, Tesla, and other “e...
Pfizer, Moderna and J&J Face Shareholder Pressure to Broaden Covid-19 Vaccine Access
Socially conscious investors and global-health activists are turning to shareholders to press Covid-19 vaccine manufacturers Pfizer Inc., Moderna Inc. and Johnson & Johnson to make more of their s...
Moderna Stock Plunges Despite ‘Vaccine Day’ Touting 31 New Shots And $21 Billion In Sales—Here’s Why
Topline Though Moderna hosted an investor seminar Thursday touting the firm’s growing vaccine pipeline and climbing sales, shares of the Cambridge, Mass.-based biotech firm plunged on Friday as ...
Covid-19 Vaccine Makers Face a New Rival as GlaxoSmithKline and Sanofi Prepare to Enter the Ring
As new Covid-19 cases fall, the postpandemic vaccine market grows more interesting. On Wednesday, GlaxoSmithKline and Sanofi, two of the world’s largest vaccine makers, said they would submit a Covid ...
Moderna (MRNA) Q4 2021 earnings
The Moderna Covid-19 vaccine is prepared for administration ahead of a free distribution of over the counter rapid Covid-19 test kits to people receiving their vaccines or boosters at Union Station in...
Moderna’s stock has tumbled enough for a long-time bear to say stop selling
Shares of Moderna Inc. MRNA, -4.45% slumped 2.3% toward an eight-month low in morning trading Friday, and have tumbled 26.5% amid a six-day losing streak, enough for formerly bearish BofA Securities a...
Losses Top $130 Billion After Scientists Find Covid Boosters Aren’t Halting Omicron Infections
Topline Battered by a steep broad-market selloff this week, Moderna shares fell for a sixth-straight day Friday as experts questioned whether Covid-19 vaccine sales alone will help justify the firm...
Johnson & Johnson’s got a new CEO and a plan to split the company in two. Here’s what else to expect out of J&J’s earnings
Johnson & Johnson JNJ, -0.31% has long been viewed as a bellwether stock for other health care companies, given its early slot in the earnings calendar and a business model that spans everything f...
A Dozen Favorite Stocks To Buy For 2022 From Argus Research
Investment stock market Entrepreneur Business Man discussing and analysis graph stock market … [+] trading,stock chart concept getty Argus Research is an independent Wall Street research firm. B...
Moderna and Novavax Stocks Get Whacked by Supreme Court’s Vaccine Decision
Text size A nurse takes a Moderna Covid-19 vaccines ready to be administered at a vaccination site Apu Gomes/AFP via Getty Images Novavax stock and shares of other vaccine makers fell Friday after the...
Universal flu vaccine may be next big Moderna, Pfizer mRNA development
Employees in special suits test the procedures for the manufacturing of the messenger RNA (mRNA) for the Covid-19 vaccine in German company BioNTech, in Marburg, Germany on March 29, 2021. Abdulhamid ...
‘The capitulation model for biotech is a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buy
If you want to know how much investors hate the biotech sector right now, consider this simple statistic: More than 25% of small biotech companies have stock-market capitalizations that are smaller th...